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Abstract
Background: Fibroblast growth factor 21 (FGF21) is a promising drug candidate to combat metabolic diseases.
However, high-level expression and purification of recombinant FGF21 (rFGF21) in Escherichia coli (E. coli) is difficult
because rFGF21 forms inclusion bodies in the bacteria making it difficult to purify and obtain high concentrations
of bioactive rFGF21. To overcome this problem, we fused the FGF21 with SUMO (Small ubiquitin-related modifier)
by polymerase chain reaction (PCR), and expressed the fused gene in E. coli BL21(DE3).
Results: By inducing with IPTG, SUMO-FGF21 was expressed at a high level. Its concentration reached 30% of total
protein, and exceeded 95% of all soluble proteins. The fused protein was purified by DEAE sepharose FF and Ni-
NTA affinity chromatography. Once cleaved by the SUMO protease, the purity of rFGF21 by high performance
liquid chromatography (HPLC) was shown to be higher than 96% with low endotoxin level (<1.0 EU/ml). The
results of in vivo animal experiments showed that rFGF21 produced by using this method, could decrease the
concentration of plasma glucose in diabetic rats by streptozotocin (STZ) injection.
Conclusions: This study demonstrated that SUMO, when fused with FGF21, was able to promote its soluble
expression of the latter in E. coli, making it more convenient to purify rFGF21 than previously. This may be a better
method to produce rFGF21 for pharmaceutical research and development.
Background
FGF21 is a potent regulator of glucose homeostasis [1].
It was originally identified as a hormone that stimulates
glucose uptake in adipocytes [2]. FGF21 is induced and
secreted from the liver upon fasting and acts on adipose
tissues to induce metabolic adaptation to fasting[3,4].
Specifically, FGF21 stimulates lipolysis in adipocytes, a
process which releases fatty acids into the bloodstream;
when they reach the liver, these fatty acids are converted
to ketones[3]. FGF21 is free of the proliferative and
tumorigenic effects [5-7] that are documented for other
members of the FGF family [3,8,9]. Systemic administra-
tion of FGF21 reduced plasma glucose, fructosamine,
triglycerides, insulin, and glucagon in diabetic rhesus
monkeys[10]. FGF21 administration led to significant
improvements in lipoprotein profiles, by lowering low-
density cholesterol and by raising high-density choles-
terol, as well as causing weight loss in the animals [10].
In recent years, FGF21 has been described as potential
new drug candidate to combat metabolic diseases [5,6].
However, producing FGF21 by traditional techniques,
such as plasmid recombination in E. coli, yields disap-
pointing results. Kharitonenkov’s experiment has shown
that recombinant FGF21 (rFGF21) accumulated and
formed inclusion bodies in transformed E. coli [5]. Our
previous experiments also showed that rFGF21 without
fusion expression more easily formed inclusion bodies,
and it was difficult to produce bioactive protein (data
not shown), because the inclusion bodies need to be
denatured, annealed, and purified through many chro-
matography columns.
SUMO (Small ubiquitin-related modifier) proteins are
covalently attached to and removed from specific
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any medium, provided the original work is properly cited.protein substrates in eukaryotic cells[11]. Sumoylation as
a reversible post-translational modification process has
been shown to be involved in many cellular processes
including nuclear-cytosolic transport, apoptosis, protein
activation, protein stability, stress response, and cell
cycle progression[11,12]. In recent years, SUMO has
become an effective biotechnological tool as a fusion
system to enhance soluble expression of proteins and
decrease proteolytic degradation, which could not be
achieved by traditional expression systems[13,14].
SUMO is then post-translationally enzymatically cleaved
from the desired protein by SUMO C-terminal hydro-
lases-isopeptidases [13]. Proteins such as, SARS virus
protein[15], MMP13[16], EGF[17], metallothionein[18],
and KGF2[19] have been successfully expressed and
purified using this fusion strategy.
Recently, Ren [20] expressed FGF21 using a commer-
cial vector containing a SUMO tag and showed that
SUMO promotes the soluble expression of FGF21 in E.
coli.H o w e v e r ,n oh i g h e rl e v e lo fp u r i t yw a sa t t a i n e d
using Ni-NTA affility purification alone. Thus, we
cloned SUMO fragment and constructed an expression
plasmid containing SUMO and human FGF21. The
results show that this novel method of protein expres-
sion can promote significantly higher rFGF21 levels,
making it easier to be dissolved in the soluble fraction
for purification and producing native N-terminal recom-
binant protein with its bioactivity preserved.
Results and discussion
Synthesis of the fusion gene and construction of
pET-SUMO-FGF21 expression vector
To synthesize the fusion gene composed of SUMO and
FGF21, fourteen special primers were designed (Table 1).
The synthesis strategy is described in the Figure 1 and
the detailed procedure is included in Materials and
Methods. The PCR products of SUMO-FGF21 are shown
in Figure 2. The final PCR product was digested with two
restriction enzymes (NdeIa n dXhoI) and cloned into the
expression vector pET-20b(+). The sequence of the
recombinant plasmid was confirmed by automated DNA
sequencing. The results show that the sequence of the
SUMO-FGF21 (864 bp, SUMO 318 bp, human FGF21
546 bp) is in conformity with the prior sequence. The
sequence of the SUMO-FGF21 has been submitted the
GenBank database (accession number: GU456634).
Expression and purification of SUMO-FGF21
Recombinants were inoculated in fresh Luria-Bertani
(LB) medium, and incubated in a shaking incubator at
37°C until the OD600 was 1.0 to 1.2. Isopropyl -D-thio-
galactoside (IPTG) was then added to a final concentra-
tion of 1 mM for the induction of expression.
Recombinant bacterial cells were collected by
centrifugation and lysed by sonication. The supernatants
and pellets were collected and subjected to 12% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
The results show that the molecular weight of the
expression product is 37 kDa, which corresponds to the
predicted size of SUMO-FGF21. The target protein is
more than 30% of total cellular protein and the soluble
fraction reaches 95.2% of the total expressed recombi-
nant proteins (Figure 3A).
According to the isoelectric point of fusion protein,
DEAE Sepharose FF was chosen for the purification of
SUMO-FGF21. SDS-PAGE results show that most of
the host proteins are removed from SUMO-FGF21
after being purified with a DEAE Sepharose FF col-
umn. Furthermore, a Ni-NTA affinity column was cho-
sen for further purification. Proteins without 6 × His
tags were removed from the Ni-NTA resin using PBS
containing 10 mM and 20 mM imidazole; SUMO-
FGF21 was eluted using PBS containing 300 mM imi-
dazole. SDS-PAGE analysis of samples taken from this
step showed that the purity of SUMO-FGF21 reached
96.5% (Figure 3B).
In recent years, there have been many reports con-
cerning SUMO as an expression fusion tag. The expres-
sion level of the fusion protein containing
metallothionein, GST and SUMO was 38.4% of the total
supernatant proteins from the organism [18]. Our data
show that SUMO-FGF21 concentration is over 25% of
all soluble proteins. Expression efficiency may be
affected by molecular weight, amino acid constitution,
and the function of proteins, etc. As far as protein isola-
tion, we performed two-step purifications, which
resulted in the purity of SUMO-FGF21 reaching 96.5%.
The results show that two-step purification is helpful for
improving the purity of rFGF21, which was more suc-
cessful than one step Ni-NTA purification [20], as well
as inclusion body purification [21].
Cleavage of the SUMO domain from SUMO-FGF21 protein
and further purification of rFGF21
When the target protein was fused directly to the C-termi-
nus of SUMO, cleavage by SUMO protease 1 resulted in
the release of the target protein with the desired N-term-
inal amino acid sequence[16,22]. In our studies, the pre-
purified fusion protein was diluted and cleaved by SUMO
protease. The lysate was purified by Ni-NTA resin. SUMO
and SUMO protease containing His tags that were
affiliated by Ni-NTA resin, but rFGF21 was eluted out of
the Ni-NTA column. The results showed that rFGF21 was
highly purified by SDS-PAGE (Figure 4A) and could react
with the human FGF21 polyclonal antibody by Western
blot (Figure 4B). HPLC analysis of the target protein
showed a major peak of rFGF21, with a retention time of
14.984 min; the purity exceeded 96% (Figure 5).
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Page 2 of 9Figure 1 Schematic illustration of SUMO-FGF21 synthesis. According to the human FGF21 mRNA coding sequence and the SUMO fragment
C-terminal sequence, 21 primers were designed and synthesized. As shown in Figure 1, the SUMO-FGF21 was synthesized by primer extension
and PCR. The detailed steps are reported in Material and Methods.
Figure 2 Synthesis of SUMO-FGF21 by PCR. The strategy for synthesizing the fusion fragment is described in Materials and Methods.T h e
molecular weight of the PCR fragment containing SUMO-FGF21 is shown in Lane 1, 2 and 3. It is 864 bp in length.
Wang et al. BMC Biotechnology 2010, 10:14
http://www.biomedcentral.com/1472-6750/10/14
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batches of purified rFGF21, and the results were less than
1.0 EU/ml, which is considered acceptable compared to
commercially available proteins. These levels were also in
accordance with the standard of injection biologics listed
in the Chinese Pharmacopeia of 2005. It also suggests
that the purity of rFGF21 by this method can meet the
requirements of pharmaceutical research in vivo.
Mass spectrometric and N-terminal amino acid
sequence analysis
In order to confirm the authenticity of rFGF21, the tar-
get protein was subjected to MALDI-TOF mass spectro-
scopy analysis and N-terminal amino acid sequencing
analysis. The molecular weight of rFGF21 analyzed by
MALDI-TOF mass spectroscopy was 19.424 kDa, which
was very close to 19.411 kDa, theoretical molecular
Table 1 PCR primers for amplifying the SUMO-FGF21 fusion gene
Primer name (size) Sequence (5’-3 )
Pa(32 bp) ggaattccatatgcatcatcatcatcatcacg
Sumo linker(39 bp) tggagtcagggatggggtgaccaccaatctgttctctgt
P1(59 bp) gccggatccatgcaccccatccctgactccagtcctctcctgcaattcgggggccaagt
P2(59 bp) ctgtctgctgggcatcatctgtgtagaggtaccgctgccggacttgcccccg aattgc
P3(59 bp) gatgatgcccagcagacagaagcccacctggagatcagggaggatgggacggtgggggg
P4(59 bp) tttcagctgcaggagactttcggggctctggtcagcagcgccccccaccgtcccatcct
P5(59 bp) aagtctcctgcagctgaaagccttgaagccgggagttattcaaatcttgggagtcaaga
P6(59 bp) tacagggccccatctggccgctggcacaggaacctggatgtcttgactcccaagatttg
P7(59 bp) ggccagatggggccctgtatggatcgctccactttgaccctgaggcctgcagcttccgg
P8(59 bp) cggactggtaaacattgtatccgtcctcaagaagcagctcccggaagctgcaggcctca
P9(59 bp) tacaatgttaccagtccgaagcccacggcctcccgctgcacctgccagggaacaagtc
P10(59 bp) gaagcgagctggtcctcggggtgcagggtcccggtgtggggacttgttccctggcaggt
P11(59 bp) ccgaggaccagctcgcttcctgccactaccaggcctgccccccgcactcccggagccac
P12(59 bp) gaggagcccacatcggggggctggggggccaggattccgggtggctccgggagtgcggg
P13(59 bp) cccccgatgtgggctcctcggaccctctgagcatggtgggaccttcccagggccgaagc
P14(46 bp) ccgctcgagtcaggaagcgtagctggggcttcggccctgggaaggt
Figure 3 SDS-PAGE analysis of expression and purification of SUMO-FGF21. Bacterial containing pET-SUMO-FGF21 were induced by IPTG
for 3 h or 4 h at 37°C in Figure 3A. The results from the different treatments are shown here. M: protein molecular weight markers;Lane 1: the
supernatant of BL21 (DE3) containing pET-SUMO-FGF21 without IPTG;Lane 2: the supernatant of BL21 (DE3) containing pET- SUMO-FGF21
induced with 1 mM IPTG for 3 h; Lane 3: the supernatant of BL21 (DE3) containing pET- SUMO-FGF21 induced with 1 mM IPTG for 4 h; Lane 4:
the precipitation of BL21 (DE3) containing pET-SUMO-FGF21 induced with 1 mM IPTG for 4 h. After recombinant bacteria were treated by
sonication and centrifugation, the supernatants were loaded on a DEAE sepharose FF and Ni-NTA orderly. The purification results for SUMO-
FGF21 are shown in the Figure 3B. Lane1: protein molecular weight marker, Lane2: purified SUMO-FGF21 eluted from Ni-NTA column; Lane3:
SUMO-FGF21 eluted from DEAE sepharose FF column.
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cing result, the first five amino acids of our rFGF21 N-
terminus were H-P-I-P-D, which was in conformity with
native FGF21.
In vivo bioactivity of rFGF21
The construction of diabetic rat models is described in
Materials and Methods. We tested the effects of rFGF21
on diabetic rats. Diabetic rats were treated daily for two
weeks with high, medium, and low dosages of rFGF21
(150, 300, 600 μg/kg/d). All treatments produced signifi-
cant changes when compared with the control animals.
The statistical results are described using column graph
(Figure 6). We can see that the changes in plasma glu-
cose levels all show significant differences compared to
controls after injecting three doses of rFGF21(
lowP <
0.05 vs control,
mediumP < 0.05 vs control,
highP < 0.01 vs
control). The results also show that rFGF21 acts in a
Figure 4 SDS-PAGE analysis of SUMO-FGF21 by SUMO protease and rFGF21 assay by Western blot. The purified SUMO-FGF21 was
digested by SUMO protease at 4°C overnight. As seen in Figure 4A, rFGF21 was cut from the SUMO-FGF21 by SUMO protease. Lane1: Protein
Molecular Weight Marker. Lane2: purified rFGF21;Lane3: SUMO-FGF21 fusion protein after treatment with SUMO protease. Western blot analysis
was performed as described in Materials and Methods. Immunoacitivity of purified rFGF21 with anti-human FGF21 antibody is shown in Figure
4B. Lane1: standard FGF21 (PeproTech Comp.);Lane2: purified rFGF21.
Figure 5 HPLC analysis of purified rFGF21. The purity of rFGF21 eluted from a Ni-NTA sepharose column was further evaluated by HPLC
analysis using a C18 column. As seen from the chromatogram, the y-axis indicates the absorbance, while the x-axis represents elution time
(min). The main peak observed at 14.984 min corresponds to rFGF21.
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diabetic rats. High doses of rFGF21 result in better
effects than the other two doses. The high dose lowers
circulating glucose from 20.25 ± 5.13 mmol/L to 10.83
± 2.73 mmol/L. Compared to rFGF21, insulin displayed
more significant effects in decreasing plasma glucose
with
cP < 0.001, which is considered a significant differ-
ence between pre- and post-treatment. The different
effects might be due to different mechanism in decreas-
ing plasma glucose between insulin and FGF21. In con-
trast to insulin, which is known to function via GLUT4
translocation, FGF-21 primarily act through up-regula-
tion of cellular GLUT1[23].
Many other experiments have also documented that
FGF21 could promote the glucose uptake in adipocytes
[6] and 3T3-L1 cells [5], as well as reduce plasma glu-
cose and triglyceride in animal models of type 2 dia-
betes, such as mouse and monkey [20,24]. However,
there were some differences in rFGF21-mediated reduc-
tions in blood glucose levels attributable to different ani-
mal genotypes and treatment. In ob/ob mice, doses of
125 and 750 μg/kg/d of FGF-21 significantly lowered
blood glucose compared with vehicle treatment after 3
days of administration[5]. After 8 days of drug adminis-
tration, FGF21 treatment not only reduces fasting blood
glucose, but also improves insulin sensitivity in ob/ob
mice [24]. Notably, 100 μg/kg dose of rFGF-21 lowered
mean fasting plasma glucose from the overtly diabetic
level to near normal when administered for 6 weeks
[10]. In our studies, rFGF21 at doses of 150, 300 or 600
μg/kg/d all decreased glucose levels in diabetic mice.
Administration of FGF21 resulted in a dose-dependent
reduction in circulating levels of glucose.
Conclusions
This study demonstrates that, when fused with SUMO,
soluble expression of rFGF21 increased in E. coli;t h i s
form is also conveniently isolated rFGF21 than pre-
viously described forms. As a novel molecular chaperon
domain, SUMO increases the yield of recombinant pro-
tein and makes it easier to dissolve in the soluble frac-
tion for protein purification. This strategy can be used
as a source of reference for the expression and purifica-
tion of other proteins.
Methods
Reagents
Pyrobest® DNA Polymerase and restriction enzymes NdeI
and XhoI were purchased from TaKaRa Company (Japan).
PCR purification kit, gel extraction kit, and plasmid mini-
prep kit were obtained from the Omega Company (USA).
The expression vector pET-3c-SUMO was produced by
Engineering Research Center of Bioreactor and Pharma-
ceutical Development, Ministry of Education, Jilin Agricul-
tural University (China). DEAE Sepharose FF column and
Sepharose G50 column were purchased from GE health-
care (Sweden). Ni-NTA agarose was obtained from Invi-
trogen (USA). Human FGF21 protein was purchased from
the PeproTech Company (Korea), and anti-hFGF21 anti-
body was purchased from Santa Cruz Biotechnology Com-
pany (USA); Dr. Yadong Huang from Ji Nan University
graciously supplied us with the SUMO protease.
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Figure 6 The effects of rFGF21 on reducing plasma glucose in diabetic rats. The STZ treated diabetic rats were injected with different
doses of rFGF21 once daily for two weeks. Control: 0.9% NaCl; Low: 0.15 mg/kg rFGF21; Medium: 0.3 mg/kg rFGF21; High: 0.6 mg/kg rFGF21;
Insulin: 5U per rat. The results show that rFGF21 acts in a dose-dependent manner to reduce plasma glucose in diabetic rats, with the high dose
rFGF21 demonstrating better effects than the other doses. Compared to rFGF21, insulin displays a more significant effect in decreasing plasma
glucose.
aP < 0.05,
bP < 0.01 and
cP < 0.001 were considered as the significant difference for post-treatment compared to pre-treatment.
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T h es t r a t e g yf o rs y n t h e s i z i n gt h ef u s i o ng e n ei si l l u -
strated in Figure 1. The core fragment of SUMO was
first obtained by polymerase chain reaction (PCR),
which was performed as follows: reaction mixture con-
taining P1, P2, P3, P4, dNTP and 10 × PCR buffer were
incubated at 94°C for 4 min. Pyrobest® DNA polymerase
was added to the reaction when the temperature
decreased to 55°C. The annealing step was conducted at
55°C for 5 min and elongation was done at 72°C for 60
sec to get fragment A. Likewise, P5, P6, P7, and P8,
were reacted to form fragment B; primers P9, P10, P11,
and P12 formed fragment C, primers P11, P12, P13, and
P14 formed fragment D. Using A and B as the common
template, and P1 and P8 as the forward and reverse pri-
mers, the reaction was denatured at 94°C for 5 min.
This was followed by 30 consecutive cycles of denatura-
tion: 95°C for 30 s, annealing for 30 s at 55°C, extension
at 72°C for 1 min, and then a final single extension at
72°C for 7 min to get the fragment M. Fragments C and
D were used to create fragment N. Finally, Fragments M
and N were used to form the FGF21 fragment, accord-
ing to the previously described procedure.
Using pET3c-SUMO (plasmid containing SUMO frag-
ment) as template, Pa and the SUMO linker as the for-
ward and reverse primers, the SUMO-linker was
generated. Then, using the SUMO-linker and the FGF21
fragment as the common template, Pa and P14 as the
forward and reverse primers, the SUMO-FGF21 full-
length constructed was created using the same PCR
reaction procedure described above.
The fusion gene was digested with NdeI and XhoI, and
then ligated into previously digested pET-20b(+) to cre-
ate the new expression vector, pET-SUMO-FGF21.
Authenticity of the inserted fragment was confirmed by
restriction enzyme analysis and automated DNA
sequencing.
Expression and soluble detection of SUMO-FGF21
The recombinant plasmid, pET-SUMO-FGF21 was
transformed into Escherichia coli BL21 (DE3) cells.
SUMO-FGF21 was expressed as follows: a single trans-
formed colony was grown in 5 ml of LB medium (1%
peptone, 1% yeast extract, and 0.5% sodium chloride,
pH 7.0) containing 100 μg/ml ampicillin at 37°C with
shaking at 250 rpm. After overnight growth, 500 μlo f
culture was transferred into 50 ml of fresh LB medium
for exponential growth. When the OD600 value reached
0.6, isopropyl-b-D-thiogalactopyranoside (IPTG) was
added to the culture at a final concentration of 1 mmol/
L. The culture was then incubated for another 4 hours
at 37°C with shaking at 220 rpm. SUMO-FGF21 was
separated by 12% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE), and the amount of
fusion protein yield was measured by densitometer
scanning.
Cell medium induced under different conditions was
harvested by centrifugation at 8000 rpm for 5 min. Cell
pellets were suspended into 20 mmol/L PBS buffer and
dissolved by sonication. The suspensions were centri-
fuged at 18,000 rpm for 30 min at 4°C. The clear super-
natant was collected (soluble fraction) and the
remaining pellets (insoluble fraction) containing inclu-
sion bodies were resuspended into an equal volume of
lysis buffer. Both soluble and insoluble fractions were
analyzed by 12% SDS-PAGE.
Purification of SUMO-FGF21
The cell lysate was purified by DEAE-Sepharose FF col-
umn chromatography. SUMO-FGF21 was eluated with
buffer containing different concentrations of NaCl (100-
300 mmol/L, pH 9.0), followed by further purification
with Ni-NTA resin (Invitrogen). The Ni-NTA resin was
washed with wash buffer I (20 mmol/L PBS containing
10 mM imidazole and 150 mM NaCl, pH 8.0) until
OD280 of effluent reached base line. Contaminating pro-
teins were eluted from the column with wash buffer II
(20 mmol/L PBS containing 20 mM imidazole and 150
mM NaCl, pH 8.0). Finally, 6 × His-tagged SUMO-
FGF21 protein was collected from the column with elu-
tion buffer (20 mmol/L PBS containing 300 mM imida-
zole and 150 mM NaCl, pH 8.0). Samples taken at the
elution peak were pooled. The purity of SUMO-FGF21
was assessed using SDS-PAGE and the concentration
was evaluated by the Bradford method.
Cleavage of SUMO from SUMO-FGF21 and
purification of rFGF21
The eluted fusion protein was diluted to a concentration
of 1 mg/ml. Ten unit of SUMO protease were added to
the dilution and the mixture was incubated in high salt
b u f f e r( 5 0m MT r i s - H C l ,p H8 . 0 ,0 . 1 5MN a C l ,1m M
DTT) for 1 hr at 4°C. Following incubation, the mixture
was loaded onto an Ni-NTA resin column to obtain the
rFGF21, which was further concentrated by ultrafiltra-
tion at 4°C. The SUMO, SUMO-FGF21 and SUMO pro-
tease stayed bound to the Ni-NTA resin and only
rFGF21 was eluted from the column when washed off
the resin with elution buffer. rFGF21 was then desalted
with Sepharose G50 column.
The authenticity assay for rFGF21
The immunogenic activity of purified rFGF21 was
assayed by Western blotting. Total cellular protein was
boiled in an equal volume of sample loading buffer, a
Tris-HCl buffer (pH 6.8) containing 20% glycerol, 2.5%
SDS, 10% b-Mercaptoethanol and 0.005% bromophenol
blue. Protein samples were electrophoresed on 12%
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trophoretically transferred onto PVDF membranes, and
after overnight exposure to 3% BSA to block nonspecific
binding, the membranes were incubated with a polyclo-
nal FGF21 antibody (Santa Cruz Biotechnology Inc,
1:1000). The membranes were washed and incubated
with a 1:5000 dilution of secondary HRP-conjugated
antibody (rabbit anti-goat IgG, Amersham Biosciences
Corp.). Immunoreactive bands were visualized using a
DAB kit (Boshide Inc, Wuhan, China).
For high performance liquid chromatography (HPLC)
analysis, purified rFGF21 was desalted and then loaded
onto a C18 column. The elution was carried out using a
linear gradient of 30-70% acetonitrile at a flow rate of
0.8 ml/min in the presence of 0.1% trifluoroacetic acid
(TFA). The fractions containing rFGF21 were pooled
and subjected to N-terminal amino acid sequencing,
amino acid composition analysis and MALDI-TOF mass
spectroscopy analysis. The concentration of rFGF21 was
evaluated by the Bradford method.
Endotoxin assay
The endotoxin concentration of rFGF21 was estimated
quantitatively using the Chromogenic Tachypleus Ame-
bocyte Lysate (TAL) endpoint assay kit as described by
the manufacturer (Zhanjiang A&C Biological Ltd,
China). The assay was performed according to the kit
protocol.
In vivo activity assay of rFGF21
All procedures involving animals and their care
described here were approved by the Institutional Ani-
mal Care and Use Committee of Jilin Agricultural Uni-
versity and were performed in accordance with
institutional guidelines for animal experiments. Male
Wistar adult rats (weighting at 180-220 g) were ran-
domly divided into the high fat diet group (HFD, n =
40) and the common diet group (NC, n = 8) after being
fed a high fat diet for two months. HFD group animals
were given peritoneal injections of 35 mg/kg streptozo-
tocin (STZ, Sigma, USA), while the NC group was given
an equivalent volume of citric acid buffer. One week
later, blood was collected and the fasting plasma glucose
(FPG) was assayed. STZ treated rats with FPG = 11.1
mmol/L were chosen as type 2 diabetes models (n =
40). Subsequently, 32 diabetic rats were divided into five
groups (n = 8/group): 1) the diabetic rats treated with a
0.6 mg/kg of rFGF21 group (high dose); 2) diabetic rats
treated with a 0.3 mg/kg of rFGF21 group (medium
dose); 3) diabetic rats treated with a 0.15 mg/kg of
rFGF21 group (low dose); 4) diabetic rats treated with
insulin (5 U/day) group (positive control) and 5) diabetic
rats treated with 0.9% NaCl group (negative control). In
addition, the 8 NC rats constituted the blank control
group. Drugs were given by subcutaneous injection once
daily for two weeks.
Statistical analysis
Values are expressed as means ± S.E.M. Mean Value
Comparisons between two groups were performed using
the Student t test. Significant differences were consid-
ered at P < 0.05.
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